Puma Biotechnology
PBYI
100 hedge funds and large institutions have $75.9M invested in Puma Biotechnology in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 23 reducing their positions, and 17 closing their positions.
191% more call options, than puts
Call options by funds: $166K | Put options by funds: $57K
48% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 23
1% more funds holding
Funds holding: 99 → 100 (+1)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.58% less ownership
Funds ownership: 64.22% → 60.63% (-3.6%)
25% less capital invested
Capital invested by funds: $101M → $75.9M (-$25.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.8M |
| 2 |
BlackRock
New York
|
+$770K |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
+$744K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$644K |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$411K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.85M |
| 2 |
Millennium Management
New York
|
-$853K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$776K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$654K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$652K |
PBYI Hedge Fund Activity: Q3 2024 in Review
100 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2024, worth a combined $75.9M — down 25% from $101M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PBYI positions and 17 closed out — a net gain of 1 holder — while 34 added to existing stakes and 23 trimmed.
The largest buyer was Kennedy Capital Management, opening a new position worth an estimated $1.8M. The largest seller was Great Point Partners, exiting entirely with an estimated $4.85M sold.
- 100 institutional investors held Puma Biotechnology (PBYI) as of Q3 2024, up from 99 in Q2 2024.
- Funds reported $75.9M of Puma Biotechnology stock for Q3 2024, down 25% quarter-over-quarter.
- 18 funds opened new Puma Biotechnology positions in Q3 2024 and 17 closed out, a net change of +1 holder.
- The largest Puma Biotechnology buyer in Q3 2024 was Kennedy Capital Management, an estimated $1.8M added.
- The largest Puma Biotechnology seller in Q3 2024 was Great Point Partners, an estimated $4.85M sold.
Based on aggregated 13F filings for Q3 2024.